Scarica l'app Stockscreener
142.26
0.97%
-1.40
Dopo l'orario di chiusura:
142.26
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Is it time to cut losses on Biogen Inc.Portfolio Risk Report & Safe Entry Zone Tips - newser.com
Key metrics from Biogen Inc.’s quarterly dataQuarterly Trade Review & Capital Efficient Trading Techniques - newser.com
Is Biogen Now an Opportunity After Recent 25% Share Price Decline? - simplywall.st
Is a relief rally coming for Biogen Inc. holdersTrade Exit Summary & Verified Stock Trade Ideas - newser.com
Alzheimer's Disease Market: Epidemiology, Therapies, - openPR.com
Looking at the Changing Narrative for Biogen After Recent Pipeline and Market Developments - Yahoo Finance
3 Reasons BIIB is Risky and 1 Stock to Buy Instead - The Globe and Mail
(BIIB) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
When is the best time to exit Biogen Inc.July 2025 Review & Capital Protection Trading Alerts - newser.com
Is Biogen Inc. stock a safe buy before earningsJuly 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
Autoinjectors Market 2025: Industry Drug Delivery, Smart - openPR.com
Sector ETF performance correlation with Biogen Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Using portfolio simulators with Biogen Inc. includedInsider Selling & AI Powered Trade Plan Recommendations - newser.com
Is Biogen Inc. (IDP) stock a buy on weaknessPortfolio Update Report & Real-Time Chart Pattern Alerts - newser.com
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact - GuruFocus
Biogen (BIIB) Valuation: Assessing Market Discount After Recent Signs of Financial Stabilization - simplywall.st
Biogen sees negative impact on Q3 EPS from IPR&D expense - Seeking Alpha
Biogen expects $2 million research and development expense in Q3 2025 - Investing.com India
Biogen expects estimated charge to impact net income per diluted share for Q3 by $-0.01 - MarketScreener
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight - GlobeNewswire Inc.
Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating - MarketScreener
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - ACN Newswire
Can Biogen Inc. stock double in next 5 yearsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
Volatility clustering patterns for Biogen Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
1 Healthcare Stock to Research Further and 2 We Find Risky - FinancialContent
Eisai and Biogen's LEQEMBI IQLIK™ Named One of TIME's "Best Inventions of 2025" for Alzheimer's Treatment - Quiver Quantitative
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - PR Newswire
Is Biogen Inc. stock a top momentum playTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Biogen Inc. (BIIB) Stock Analysis: Exploring a 17% Potential Upside Amidst Robust Neurological Portfolio - DirectorsTalk Interviews
Valeo Financial Advisors LLC Invests $225,000 in Biogen Inc. $BIIB - MarketBeat
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know - The Globe and Mail
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BI - GuruFocus
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines? - Yahoo Finance
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Biogen Inc.'s (NASDAQ:BIIB) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - 富途牛牛
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
Q3 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
Using data filters to optimize entry into Biogen Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - newser.com
What to Expect From Biogen’s Q3 2025 Earnings Report - MSN
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen (NASDAQ:BIIB) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Biogen invests $250,000 into Durham Tech’s Life Sciences Center - CBS 17
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Biogen
Biogen & Stoke: Zorevunersen Shows 95% Clinical Improvement at 3 Years | BIIB Stock News - Stock Titan
Where Does Biogen Stand After Recent 7% Rally Amid Alzheimer’s Drug Developments? - simplywall.st
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB) - The Globe and Mail
Biogen's Comeback: Why The Bulls Are Finally Winning Again (NASDAQ:BIIB) - Seeking Alpha
NC governor recognizes Biogen milestone as biotech giant celebrates recent investments in Triangle - CBS 17
Is Biogen Inc. (IDP) stock a defensive play amid uncertainty2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Biogen Pledges $250,000 Donation to Durham Technical Community College to Mark 30th Year Anniversary in Research Triangle Park - Biogen
Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 - Time Magazine
Simplicity Wealth LLC Makes New $430,000 Investment in Biogen Inc. $BIIB - MarketBeat
Why Are Analysts Bullish on Biogen Inc. (BIIB) Now? - MSN
Governor Stein to celebrate Biogen's 30th anniversary, spotlight biotech growth - WCTI
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
2.17%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):